Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Letavernier

Showing results (1-10 of 152) with videos related to

Pageof 16
Sort By:
Kidney International|January 4, 2026
The authors replyThomas Robert, Emmanuel Letavernier
Nature Reviews. Urology|February 3, 2016
Stones: Tolvaptan might prevent kidney stone formationEmmanuel Letavernier, Michel Daudon
Medecine Sciences : M/S|May 27, 2016
[Calpains: a double edge sword]Emmanuel Letavernier, Laurent Baud
Journal of the American Society of Nephrology : JASN|November 16, 2007
PPARalpha contributes to tubular protectionLaurent Baud, Emmanuel Letavernier
Nutrients|March 23, 2018
Vitamin D, Hypercalciuria and Kidney StonesEmmanuel Letavernier, Michel Daudon
La Revue Du Praticien|December 6, 2018
Urinary stonesEmmanuel Letavernier, Michel Daudon
La Revue Du Praticien|February 6, 2019
The analysis of the stone tells its historyEmmanuel Letavernier, Michel Daudon
Transplantation Reviews (Orlando, Fla.)|July 18, 2008
mToR inhibitors-induced proteinuria: mechanisms, significance, and managementEmmanuel Letavernier, Christophe Legendre
Nephrologie & Therapeutique|April 29, 2021
[Effect of stiripentol on urine oxalate excretion]Emmanuel Letavernier, Michel Daudon
Current Opinion in Nephrology and Hypertension|May 27, 2020
Stiripentol identifies a therapeutic target to reduce oxaluriaEmmanuel Letavernier, Michel Daudon
Pageof 16

Showing results (1-10 of 152) with videos related to

Sort By:
Pageof 16
Kidney International|January 4, 2026
The authors replyThomas Robert, Emmanuel Letavernier
Nature Reviews. Urology|February 3, 2016
Stones: Tolvaptan might prevent kidney stone formationEmmanuel Letavernier, Michel Daudon
Medecine Sciences : M/S|May 27, 2016
[Calpains: a double edge sword]Emmanuel Letavernier, Laurent Baud
Journal of the American Society of Nephrology : JASN|November 16, 2007
PPARalpha contributes to tubular protectionLaurent Baud, Emmanuel Letavernier
Nutrients|March 23, 2018
Vitamin D, Hypercalciuria and Kidney StonesEmmanuel Letavernier, Michel Daudon
La Revue Du Praticien|December 6, 2018
Urinary stonesEmmanuel Letavernier, Michel Daudon
La Revue Du Praticien|February 6, 2019
The analysis of the stone tells its historyEmmanuel Letavernier, Michel Daudon
Transplantation Reviews (Orlando, Fla.)|July 18, 2008
mToR inhibitors-induced proteinuria: mechanisms, significance, and managementEmmanuel Letavernier, Christophe Legendre
Nephrologie & Therapeutique|April 29, 2021
[Effect of stiripentol on urine oxalate excretion]Emmanuel Letavernier, Michel Daudon
Current Opinion in Nephrology and Hypertension|May 27, 2020
Stiripentol identifies a therapeutic target to reduce oxaluriaEmmanuel Letavernier, Michel Daudon
Pageof 16